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Improved postsurgical management to prevent subsequent
progression among the 70% of patients with renal cell cancer
(RCC) who present to urologic surgeons with initially localized
RCC is an area of great need in urologic oncology. When con-
sidering all comers, 50% of patients with initially localized RCC
will develop recurrent disease in the 10 years after nephrectomy.1
This rate of recurrence rises to. 75% for patients deemed at high
risk for recurrence,2 at which point the disease is rarely curable.
Postsurgery, patients with RCC are often surprised to hear that,
unlike in other cancers, there is no evidence that adjuvant therapy
improves survival. As such, the urologic oncology clinical and
patient communities have been closely following the rapidly
emerging evidence around use of targeted therapy as an adjuvant
strategy for initially localized RCC. The assumption that agents
that have proven successful in treating metastatic RCC will also be
efﬁcacious in micrometastatic RCC led to the development of
a series of RCC adjuvant tyrosine kinase inhibitor (TKI) trials,
recruitment for which started in 2007.3 The results of the PROTECT
(Pazopanib As Adjuvant Therapy in Localized/Locally Advanced
RCC After Nephrectomy) trial,4 published in the article that ac-
companies this editorial, represent the third report of a double-blind,
placebo-controlled, randomized phase III trial of adjuvant vascular
endothelial growth factor receptor (VEGFR) TKIs. PROTECT is
reported at a fascinating juncture with our existing evidence base
consisting of one large negative study of adjuvant sunitinib or soraﬁnib
(ASSURE [Adjuvant Sorafenib or Sunitinib for Unfavorable Renal
Carcinoma])5 and one smaller positive study of adjuvant sunitinib (S-
TRAC [Sunitinib as Adjuvant Treatment for Patients at High Risk of
Recurrence of Renal Cell Carcinoma Following Nephrectomy])
demonstrating a hazard ratio (HR) of 0.76 (P5 .03), providing a 1.2-
year delay in disease-free survival (DFS) versus placebo.6
In the PROTECT trial, patients with Karnofsky Performance
Status of $ 80% and pT2, G3-G4, N0; pT3, Gany, N0; pT4, Gany,
N0; or pTany, Gany, N1 disease were randomly assigned at a one-
to-one ratio to placebo or pazopanib for 1 year. Initially, patients
were treated with a starting dose of pazopanib 800 mg once daily
(403 randomly assigned patients). However, because of a higher-
than-expected trial discontinuation rate, a decision was made by the
sponsor and study steering committee (rather than being mandated
by the independent data monitoring committee) to reduce this
starting dose to 600 mg once daily (1,135 randomly assigned pa-
tients). Critically, the primary analysis, which originally included
all patients, was also altered, to analysis of DFS only in those pa-
tients receiving the 600-mg starting dose of pazopanib, effectively
restarting the study. Methodologically, this would seem to be the
purest way in which to assess the outcome of PROTECT. However, it
is interesting to note that trial-level starting-dose reductions are
common in adjuvant trials. In ASSURE, the starting dose of
sunitinib was reduced from 50 to 37.5 mg and of sorafenib from
400 mg twice per day to once daily, with the aim of dose esca-
lation; however, the primary analysis remained DFS of the entire
cohort.5 The intended beneﬁt in PROTECT of reducing the
pazopanib starting dose was to reduce toxicity and trial dis-
continuation. However, despite a comparable toxicity proﬁle of
pazopanib in this localized RCC cohort relative to metastatic RCC
studies, this aim did not come to fruition, with the discontin-
uation rate remaining similar after the dose reduction (39% of
intention-to-treat (ITT) patients receiving 800 mg discontinued
pazopanib v 35% of ITT patients receiving 600 mg, compared
with a maximum of 24% in metastatic RCC pazopanib trials7). In
retrospect, had the PROTECT trial management group followed
the lead of previous RCC adjuvant studies and analyzed the DFS
of the entire cohort, PROTECT may well have been a positive
study. One of the key learning points from PROTECT is how
different patient tolerance of toxicity is among patients with non-
metastatic disease versus those with metastatic disease, for whom
drug therapy is usually the sole treatment. Thus, successful direct
translation of drug dosing and administration schedules from the
metastatic setting is not guaranteed. However, a related ﬁnding from
PROTECTwas that quality of life returned to baseline levels as soon
as treatment was stopped; indeed, the only clinically relevant re-
duction in quality of life was at 8 weeks after starting the drug,
suggesting that good counseling, especially early in the study, may be
essential in preventing patient discontinuation of the study drug.
On initial inspection of the survival curves and HRs of the ITT
800-mg versus placebo cohorts, it seems there might be beneﬁt in
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this adjuvant pazopanib dose, with a signiﬁcant improvement in
DFS (HR, 0.69; P 5 .02), which in turn pushed the ITT all-patient
cohort to a signiﬁcantly improved DFS with pazopanib over
placebo (HR, 0.80; P5 .01). However, the ITT 800-mg cohort was
an underpowered and nondeﬁnitive secondary end point, which
included only 198 patients receiving pazopanib and 205 receiving
placebo versus 571 and 564 patients, respectively, in the primary
end point ITT 600-mg cohort. Although one cannot be deﬁnitive,
there seems to be a marked difference in DFS rate in the placebo
group between ITT patients receiving 600 versus 800 mg (3-years
DFS rate, 64% v 56%, respectively; whereas DFS rates for pazopanib-
treated ITT patients were similar at 67% and 66% for 600 v 800 mg,
respectively). The reason for such a difference in sequentially
recruited patients in a randomized controlled trial is unclear; the
authors believe it may have resulted from missing demographic
data; nonetheless, this difference may account for the signiﬁcant
improvement in DFS at the ITT 800-mg dose.
How should we interpret PROTECT in the context of ASSURE
and S-TRAC? The PROTECT authors suggest that all three ad-
juvant studies reported to date enrolled a similar population of
patients. However, the level of interstudy heterogeneity appears to
make cross-study comparisons even more invalid than usual. Key
eligibility criteria differed across the three studies. First, PROTECT
and S-TRAC recruited patients with clear cell or predominantly
clear cell RCC, whereas in ASSURE, 20% of patients had non–clear
cell RCC. Second, there was limited uniformity in patient prog-
nostic risk inclusion criteria. PROTECT claimed to risk stratify
using stage, size, grade and necrosis, but the scores were not tab-
ulated, and necrosis was not included8; similarly, S-TRAC and
ASSURE inclusion criteria were based on the University of
California Los Angeles Integrated Staging System (UISS), but the
studies did not adhere rigidly to the deﬁned criteria.9 When
mapped onto the UISS, all three studies included intermediate- and
high-risk patients,9 but of the three trials, ASSURE had the least
aggressive proﬁle (setting lower end of inclusion criteria at pT1b,
G3/4, N0 disease), followed by PROTECT (including patients with
pT2, G3/4, N0 disease) and S-TRAC, with the highest risk proﬁle
(including patients with pT3, Gany, N0 disease). S-TRAC also in-
cluded a modiﬁed very high-risk UISS group as a preplanned
secondary analysis, where a 2.2-year delay in DFS after sunitinib
therapy was seen (HR, 0.74; P 5 .04).6 In all three studies, . 80%
of included patients had pT3 disease, the majority of whom will
have had pT3a disease; this is a heterogeneous group of patients
when considering sinus fat versus perirenal fat versus renal vein
invasion, with markedly different outcomes, also dependent on
tumor size.10,11 These concepts emphasize that more advanced
and uniﬁed prognostic scores, potentially including molecular
stratiﬁers such as the RNA-based recurrence score,12,13 are needed
for the design of future adjuvant studies. In the meantime, access to
patient-level, rather than trial-level, data from the three adjuvant
trials is necessary to allow accurate meta-analysis.
Putting aside these issues and the possibility that PROTECT
might have been positive using the original planned analysis,
PROTECT follows ASSURE in representing another large negative
study of an adjuvant VEGFR TKI in initially localized RCC. As in
both S-TRAC and ASSURE, overall survival, which would seem to
be of key importance to patients in deciding whether to begin
adjuvant therapy, was a secondary end point in PROTECT. As in
the other studies, PROTECT did not show a signiﬁcant survival
advantage for pazopanib after a median of 30 months of follow-up,
although the data are currently immature.
The only positive RCC adjuvant study to date, S-TRAC, was also
the only one that did not require a protocol amendment for the starting
dose. All patients began sunitinib treatment at 50 mg once daily (dose
reduction rate, 34%; discontinuation rate, 28%).6 Taken together with
the information from PROTECT (ie, ITT patients receiving 800 mg
seemed to have signiﬁcantly improved DFS), these data indicate that
cumulative dose of VEGFR TKI might be key in delaying recurrence.
Another difference in the S-TRAC study was that it was the
only study with central imaging review for both baseline and
primary end point. There was no central imaging review in ASSURE,
and there was only baseline review in PROTECT. It is impossible to
conclude that this was a deﬁning factor in the results of ASSURE or
PROTECT, but it was a differentiating feature of the S-TRAC design.
On the basis of these data, should central imaging review at baseline
and primary end point now be standard?
We now have one positive study, one negative study, and one
negative study with tantalizing secondary end points. There are
a series of other RCC adjuvant TKI studies due to report over the
next few years3: SORCE (a phase III randomised double-blind
study comparing SOrafenib with placebo in patients with Resected
primary renal CEll carcinoma at high or intermediate risk of
relapse; patients randomly assigned at a three-to-three-to-two ratio
to sorafenib for 1 year followed by placebo for 2 years, sorafenib
for 3 years, or placebo for 3 years; ClinicalTrials.gov identiﬁer:
NCT00492258), EVEREST (EVErolimus for Renal Cancer Ensuing
Surgical Therapy; everolimus v placebo in nine courses of 6 weeks;
ClinicalTrials.gov identiﬁer: NCT01120249), and ATLAS (Adju-
vant Axitinib Therapy of Renal Cell Cancer in High Risk Patients;
axitinib v placebo for 3 years; ClinicalTrials.gov identiﬁer:
NCT01599754). On the basis of our now greater understanding of
how patients with nonmetastatic disease respond to treatment with
targeted therapy, there will be several unique points on which each
upcoming trial will provide information. First, we will gain the ﬁrst
data on axitinib and everolimus in the adjuvant setting. In all three
published adjuvant trials, there was a perceptible separation of the
DFS Kaplan-Meier curve during receipt of therapy; furthermore, the
DFS advantage in S-TRAC was 1.2 years, suggesting that the study
drug may extend DFS for the duration of treatment. As such,
secondly, we will also further deﬁne the role of more chronic
treatment based on the SORCE and ATLAS trials, where patients
receive 3 years of therapy. Third, the strategies of different ad-
juvant studies for keeping patients on higher doses of drug for
longer will be scrutinized in more detail, because cumulative dose
seems to be critical in the adjuvant setting. It does seem that the
dosing tolerated by metastatic patients is not tolerated in the
same proportion of patients postnephrectomy for localized disease.
Fourth, a better understanding of how to counsel patients on what
they can expect is needed fromprevious and ongoing adjuvant studies.
Finally, and perhaps most importantly, none of the adjuvant studies
have shown any overall survival beneﬁt (S-TRAC showed a delay in
progression only), placing a focus on what exactly patients would
expect to gain from a period of adjuvant therapy with its concomitant
toxicity. In particular, is deferment of potentially symptomatic me-
tastases (and for how long), without prolongation of life, desired by
patients? It is for reasons such as this that patients must be involved in
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the design of clinical trials, especially in a setting where approximately
50% patients will not develop relapse without systemic therapy after
surgery but would be exposed to associated drug toxicity.
As we shift focus back to our current clinical practice, adjuvant
therapy is not standard of care after surgery for initially localized
RCC, and PROTECT does not provide further evidence altering
this viewpoint. As such, we are now starting to recruit patients to
the next era of adjuvant RCC trials using immunooncology
agents.3 However, PROTECT has provided a greater understanding
of the nuances of the effect of VEGFRTKIs in pT21 clear cell RCC
after surgery and, importantly for ongoing immunooncology
adjuvant trials, has not provided any suggestion that the control
arm of these studies needs to be altered, at least not yet.
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